News

• Moderna Inc. declined 20% to $33.72 after the biotech company lowered its 2025 revenue range to between $1.5 billion and $2.5 billion, a decrease of $1 billion from the previous estimate as the company continues its operating costs. 
  
  The revised outlook is lower than the previous outlook between $2.5 billion and $3.5 billion issued in September. 
  
  Jan 13, 2025
• Moderna Inc. declined 20% to $33.72 after the biotech company lowered its 2025 revenue range to between $1.5 billion and $2.5 billion, a decrease of $1 billion from the previous estimate as the company continues its operating costs. 
  
  The revised outlook is lower than the previous outlook between $2.5 billion and $3.5 billion issued in September.  Less
  
  Jan 13, 2025


• Lululemon Athletica increased 1.9% to $403.29 after the specialty apparel retailer lifted its fourth quarter sales outlook. 
  
  The company now estimated sales to increase between 11% and 12% to between $3.56 billion and $3.58 billion, higher than the previous range between $3.48 billion and $3.51 billion. 
  
  The company is now forecasting its earnings per share to range between $5.81 and $5.85 compared to the previous estimate between $5.56 and $5.64. 
  
  Jan 13, 2025
• Lululemon Athletica increased 1.9% to $403.29 after the specialty apparel retailer lifted its fourth quarter sales outlook. 
  
  The company now estimated sales to increase between 11% and 12% to between $3.56 billion and $3.58 billion, higher than the previous range between $3.48 billion and $3.51 billion. 
  
  The company is now forecasting its earnings per share to range between $5.81 and $5.85 compared to the previous estimate between $5.56 and $5.64.  Less
  
  Jan 13, 2025

Executive/
Director

Links

YTD

Earnings

Annual Returns

52 Week
High/Low

Annual
Earnings

Chart

Trading Volume

Outstanding Shares
(In Millions) +

Financial Statements
+

SEC Filings

Financial Ratios